{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T15:23:36Z","timestamp":1761578616371},"reference-count":48,"publisher":"BMJ","issue":"21","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1136\/heartjnl-2016-310844","type":"journal-article","created":{"date-parts":[[2017,6,9]],"date-time":"2017-06-09T00:50:27Z","timestamp":1496969427000},"page":"1670-1679","update-policy":"http:\/\/dx.doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":20,"title":["PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype?"],"prefix":"10.1136","volume":"103","author":[{"given":"Savvas","family":"Hadjiphilippou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kausik K","family":"Ray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,6,8]]},"reference":[{"key":"key-10.1136\/heartjnl-2016-310844-1","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","article-title":"Variation in PCSK9 and HMGCR and risk of Cardiovascular Disease and Diabetes","volume":"375","author":"Ference","year":"2016","journal-title":"N Engl J Med"},{"key":"key-10.1136\/heartjnl-2016-310844-2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"key-10.1136\/heartjnl-2016-310844-3","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.atherosclerosis.2014.08.038","article-title":"Sorting an LDL receptor with bound PCSK9 to intracellular degradation","volume":"237","author":"Leren","year":"2014","journal-title":"Atherosclerosis"},{"key":"key-10.1136\/heartjnl-2016-310844-4","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1194\/jlr.R026658","article-title":"The PCSK9 decade","volume":"53","author":"Lambert","year":"2012","journal-title":"J Lipid Res"},{"key":"key-10.1136\/heartjnl-2016-310844-5","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1161\/01.ATV.20.4.1089","article-title":"Genetic localization to chromosome 1p32 of the third locus for familial hypercholesterolemia in a Utah kindred","volume":"20","author":"Hunt","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key-10.1136\/heartjnl-2016-310844-6","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/S0022-2275(20)33515-X","article-title":"Evidence for a third genetic locus causing familial hypercholesterolemia. A non-LDLR, non-APOB kindred","volume":"40","author":"Haddad","year":"1999","journal-title":"J Lipid Res"},{"key":"key-10.1136\/heartjnl-2016-310844-7","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"issue":"5-6","key":"key-10.1136\/heartjnl-2016-310844-8","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1440-1681.2006.04403.x","article-title":"Antisense oligonucleotides: from design to therapeutic application","volume":"33","author":"Chan","year":"2006","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"key-10.1136\/heartjnl-2016-310844-9","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/bcp.12738","article-title":"Antisense-mediated reduction of proprotein convertase subtilisin\/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial","volume":"80","author":"van Poelgeest","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"key-10.1136\/heartjnl-2016-310844-10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bbrc.2008.07.106","article-title":"PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide","volume":"375","author":"Shan","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"key-10.1136\/heartjnl-2016-310844-11","doi-asserted-by":"crossref","first-page":"A1372","DOI":"10.1016\/S0735-1097(14)61372-3","article-title":"LDL cholesterol reduction with bms-962476, an adnectin inhibitor of Pcsk9: results of a single ascending dose study","volume":"63","author":"Stein","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"key-10.1136\/heartjnl-2016-310844-12","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa1614062","article-title":"Lipid-Reduction variability and Antidrug-Antibody formation with Bococizumab","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"key-10.1136\/heartjnl-2016-310844-13","doi-asserted-by":"crossref","first-page":"11915","DOI":"10.1073\/pnas.0805434105","article-title":"Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates","volume":"105","author":"Frank-Kamenetsky","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key-10.1136\/heartjnl-2016-310844-14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(13)61914-5","article-title":"Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial","volume":"383","author":"Fitzgerald","year":"2014","journal-title":"Lancet"},{"key":"key-10.1136\/heartjnl-2016-310844-15","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at High Cardiovascular risk with Elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N Engl J Med"},{"key":"key-10.1136\/heartjnl-2016-310844-16","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","article-title":"Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial","volume":"311","author":"Robinson","year":"2014","journal-title":"JAMA"},{"key":"key-10.1136\/heartjnl-2016-310844-17","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab","volume":"63","author":"Koren","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"key-10.1136\/heartjnl-2016-310844-18","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"DESCARTES investigators. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N Engl J Med"},{"key":"key-10.1136\/heartjnl-2016-310844-19","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"key-10.1136\/heartjnl-2016-310844-20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"key-10.1136\/heartjnl-2016-310844-21","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"key-10.1136\/heartjnl-2016-310844-22","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of Evolocumab vs Ezetimibe in Patients with Muscle-Related statin intolerance: the GAUSS-3 Randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"key":"key-10.1136\/heartjnl-2016-310844-23","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"ODYSSEY LONG TERM investigators. efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"key-10.1136\/heartjnl-2016-310844-24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2217\/fca.14.82","article-title":"ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks","volume":"11","author":"Roth","year":"2015","journal-title":"Future Cardiol"},{"key":"key-10.1136\/heartjnl-2016-310844-25","doi-asserted-by":"crossref","first-page":"ehv370","DOI":"10.1093\/eurheartj\/ehv370","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein","year":"2015","journal-title":"Eur Heart J"},{"key":"key-10.1136\/heartjnl-2016-310844-26","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J Clin Lipidol"},{"key":"key-10.1136\/heartjnl-2016-310844-27","doi-asserted-by":"crossref","first-page":"e003421","DOI":"10.1161\/JAHA.116.003421","article-title":"Efficacy and safety of Alirocumab 150\u00a0mg Every 4\u00a0Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study","volume":"5","author":"Stroes","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"key-10.1136\/heartjnl-2016-310844-28","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","article-title":"Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study","volume":"380","author":"Giugliano","year":"2012","journal-title":"Lancet"},{"key":"key-10.1136\/heartjnl-2016-310844-29","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","article-title":"Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease, SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy","volume":"59","author":"McKenney","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"key-10.1136\/heartjnl-2016-310844-30","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","article-title":"Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 inhibition in Heterozygous Familial Hypercholesterolemia disorder (RUTHERFORD) randomized trial","volume":"126","author":"Raal","year":"2012","journal-title":"Circulation"},{"key":"key-10.1136\/heartjnl-2016-310844-31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","article-title":"Effect of a monoclonal antibody to PCSK9, REGN727\/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial","volume":"380","author":"Stein","year":"2012","journal-title":"Lancet"},{"key":"key-10.1136\/heartjnl-2016-310844-32","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","article-title":"Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial","volume":"308","author":"Sullivan","year":"2012","journal-title":"JAMA"},{"key":"key-10.1136\/heartjnl-2016-310844-33","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.jacc.2016.09.928","article-title":"Determining when to add Nonstatin therapy: a quantitative approach","volume":"68","author":"Robinson","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"key-10.1136\/heartjnl-2016-310844-34","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","article-title":"Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia","volume":"67","author":"Khera","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"key-10.1136\/heartjnl-2016-310844-35","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jacl.2015.12.009","article-title":"Quality of life in patients treated with lipoprotein apheresis","volume":"10","author":"Rosada","year":"2016","journal-title":"J Clin Lipidol"},{"key":"key-10.1136\/heartjnl-2016-310844-36","doi-asserted-by":"crossref","first-page":"139","DOI":"10.18553\/jmcp.2013.19.2.139","article-title":"Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"19","author":"Robinson","year":"2013","journal-title":"J Manag Care Pharm"},{"key":"key-10.1136\/heartjnl-2016-310844-37","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1161\/CIRCULATIONAHA.116.024604","article-title":"Reductions in atherogenic lipids and Major cardiovascular events: a pooled analysis of 10 ODYSSEY trials comparing Alirocumab with Control","volume":"134","author":"Ray","year":"2016","journal-title":"Circulation"},{"key":"key-10.1136\/heartjnl-2016-310844-38","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Open-Label Study of Long-Term evaluation against LDL cholesterol (OSLER) Investigators. efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"key-10.1136\/heartjnl-2016-310844-39","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/eurheartj\/ehv563","article-title":"The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis","volume":"37","author":"Lipinski","year":"2016","journal-title":"Eur Heart J"},{"key":"key-10.1136\/heartjnl-2016-310844-40","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/clc.22678","article-title":"Design and rationale of the EBBINGHAUS trial: a phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial","volume":"40","author":"Giugliano","year":"2017","journal-title":"Clin Cardiol"},{"key":"key-10.1136\/heartjnl-2016-310844-41","unstructured":"Giugliano RP , Mach F , Zavitz K , et al . EBBINGHAUS: a cognitive study of patients enrolled in the FOURIER trial. http:\/\/www.timi.org\/uploads\/pdfs\/ACC.17\/EBBINGHAUS_LBCT_ACC_2017_Final_shown_(2).pdf (accessed 29 Mar 2017)."},{"key":"key-10.1136\/heartjnl-2016-310844-42","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMc1616623","article-title":"Antidrug antibodies in patients treated with Alirocumab","volume":"376","author":"Roth","year":"2017","journal-title":"N Engl J Med"},{"key":"key-10.1136\/heartjnl-2016-310844-43","article-title":"FOURIER Steering Committee and investigators. Evolocumab and clinical outcomes in patients with Cardiovascular Disease","author":"Sabatine","journal-title":"N Engl J Med"},{"key":"key-10.1136\/heartjnl-2016-310844-44","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: the GLAGOV Randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"key-10.1136\/heartjnl-2016-310844-45","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.jacc.2010.02.026","article-title":"Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome","volume":"55","author":"Nicholls","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"key-10.1136\/heartjnl-2016-310844-46","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"IMPROVE-IT investigators. Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"key-10.1136\/heartjnl-2016-310844-47","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"key-10.1136\/heartjnl-2016-310844-48","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"SPIRE Cardiovascular Outcome investigators. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2016-310844","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T11:12:05Z","timestamp":1659093125000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2016-310844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,8]]},"references-count":48,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2017,10,12]]},"published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1136\/heartjnl-2016-310844"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2016-310844","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,8]]}}}